# OnCo record extensive-stage-sclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/extensive-stage-sclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "extensive-stage-sclc" ;
  schema:name "Extensive-stage small-cell lung cancer"@en ;
  schema:alternateName "ES-SCLC"@en, "Extensive-disease small-cell lung cancer"@en, "Metastatic small-cell lung cancer"@en, "Stage IV small-cell lung cancer"@en ;
  schema:description "Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."@en ;
  schema:url <https://onco.cc/cancers/extensive-stage-sclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Small-cell_carcinoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Small-cell_carcinoma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/benmelstobart/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/ryz101/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/pharmamar/>, <https://onco.cc/companies/henlius/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/> ;
  onco:pathways <https://onco.cc/pathways/sclc-signalling/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/limited-extensive-stage/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/consolidation-therapy/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/step-up-dosing/>, <https://onco.cc/terms/pci-term/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/platinum-sensitivity/> ;
  onco:trials <https://onco.cc/trials/impower133/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/trials/astrum-005/>, <https://onco.cc/trials/imforte/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/trials/dellphi-305/>, <https://onco.cc/trials/ideate-lung02/>, <https://onco.cc/trials/slotman-pci-es-sclc/>, <https://onco.cc/trials/takahashi-pci/>, <https://onco.cc/trials/dllevate/> ;
  onco:people <https://onco.cc/people/luis-paz-ares/>, <https://onco.cc/people/charles-rudin/>, <https://onco.cc/people/martin-reck/>, <https://onco.cc/people/cheng-ying/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/> ;
  onco:pipeline <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/trials/ideate-lung02/>, <https://onco.cc/trials/dellphi-305/>, <https://onco.cc/drugs/ryz101/>, <https://onco.cc/drugs/zl-1310/>, <https://onco.cc/trials/dllevate/>, <https://onco.cc/ideas/idea-sclc-subtype-directed/>, <https://onco.cc/pairings/tarlatamab-vs-idxd-sequence/>, <https://onco.cc/pairings/chemo-io-then-maintenance-sclc/>, <https://onco.cc/ideas/idea-mri-surveillance-replaces-pci/> ;
  onco:standardOfCare <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/trials/impower133/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/trials/imforte/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/trials/astrum-005/>, <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/benmelstobart/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/step-up-dosing/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/terms/pci-term/>, <https://onco.cc/trials/slotman-pci-es-sclc/>, <https://onco.cc/trials/takahashi-pci/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/terms/wbrt/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/terms/consolidation-therapy/> .